EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

BRCA mutation status and olaparib-related toxicity during maintenance therapy: a real-world retrospective cohort study

Yuewen Gao, Minxue Gai, Hongyang Zhang, Hongqi Li

Frontiers in Oncology · 30.03.2026 · 16

DOI: 10.3389/fonc.2026.1789787 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Oncology, online erschienen am 30.03.2026. Verfasst von Yuewen Gao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Olaparib is a standard maintenance therapy for epithelial ovarian cancer, particularly in patients with BRCA mutations. While BRCA status is an established predictive biomarker for efficacy, its potential impact on treatment-related toxicity remains uncertain. We evaluated the association between BRCA mutation status and the incidence and severity of olaparib-related adverse events in a real-world cohort.

Method

This retrospective observational study included patients with epithelial ovarian cancer who received olaparib maintenance therapy at Shandong Provincial Hospital between August 2018 and October 2021. Patients were stratified by BRCA mutation status. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and analyzed at the patient level. Clinically relevant adverse events were defined as grade ≥2, as these typically require medical intervention, closer monitoring, or dose modification. Multivariable logistic regression was performed to adjust for potential confounders.

Results

A total of 40 patients were included (24 BRCA-mutant and 16 BRCA wild-type). Clinically relevant adverse events (grade ≥2) occurred more frequently in the BRCA-mutant group than in the BRCA wild-type group (62.5% vs. 18.8%; OR 7.22, 95% CI 1.65–27.42; p = 0.0097). In multivariable analysis adjusting for age and prior chemotherapy cycles, BRCA mutation status remained significantly associated with grade ≥2 adverse events (OR 8.66, 95% CI 1.67–44.81; p = 0.010). Treatment discontinuation due to adverse events was uncommon in both groups.

Conclusions

In this real-world retrospective cohort, BRCA mutation status was associated with increased risk of clinically significant olaparib-related toxicity. These findings suggest that BRCA mutation status may help identify patients at higher risk of adverse events and support closer toxicity monitoring and individualized dose management during maintenance therapy.

Schlagwörter

Stichwörter der Autor:innen

BRCA mutationPARP inhibitoradverse eventsepithelial ovarian cancerolaparibtoxicity

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Gynecology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.

Zitieren

APA

Gao, Y., Gai, M., Zhang, H., & Li, H. (2026). BRCA mutation status and olaparib-related toxicity during maintenance therapy: a real-world retrospective cohort study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1789787

Vancouver

Gao Y, Gai M, Zhang H, Li H. BRCA mutation status and olaparib-related toxicity during maintenance therapy: a real-world retrospective cohort study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1789787

BibTeX
@article{Gao2026,
  author = {Gao, Yuewen and Gai, Minxue and Zhang, Hongyang and Li, Hongqi},
  title = {BRCA mutation status and olaparib-related toxicity during maintenance therapy: a real-world retrospective cohort study},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1789787}
}
Kostenlos starten →